zurück Home

Ösophagus - Karzinom: Studien

ARTDECO

Bei der definitiven Radio-Chemotherapie des Ösophagus-Ca resultiert die Dosisescalation von 50,4 auf 61,6 nicht in einer besseren lokalen Kontrolle. (12)

CROSS-Trial

preoperative Radiochemotherapie besser als nur OP

PRODIGE5 / ACCORD17

Die Radiochemotherapie mit FOLFOX(Carboplatin-5-FU-Leukovorin) erzielt beim inoperablen Ösophaguskarzinom ein gleich gutes progressionsfreies Überleben wie mit Cisplatin-5-FU.

RAMONA

Nivolumab und Ipilimumab als second-line - Therapie bei  Patienten > 64 Jahre mit fortgeschrittenem SCC des Ösophagus (in Planung)

FREGAT

Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer

NEOCRTEC5010 (11)

Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus

Intergroup 0123 (2)

Radiochemotherapie mit 50,4 Gy v. 64,8Gy. Chemotherapie mit Carboplatin, 5-FU und Paclitaxel. 11 therapiebedingte Todesfälle bei 64,8Gy, 2 Todesfälle bei 50,4Gy

RTOG 02-46

A phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer.

RTOG 01-13

Phase II randomized trial of two nonoperative regimens (A, B) of induction chemo followed by ChemoRT with localized carcinoma of the esophagus

RTOG 94-05 (10)

Phase III trial of combined modality therapy for esophageal cancer: high-dose (A) vs. Standard-dose RT (B)

RTOG 85-01 (1)

Radiochemotherapie: 27% 5a-survival. Nur Radiotherapie: 0% 5a-survival.

LEOPARD

Definitive radiochemotherapy with 5-FU / cisplatin plus/minus cetuximab in unresectable locally advanced esophageal cancer: a phase II study. Offene Studie, Studienleiter: Dirk Rades

EORTC

 

ARO 2015-4, ESOPEC

Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus. Phase III. Brunner, Freiburg

REAL-3

Panitumumab

FFCD 9101

Im Stadium I und II des Ösophaguskarzinoms verbessert die praeoperativer Radiochemotherapie das Resamtüberleben und die Rate der Ro-Resektionen nicht, erhöht aber die perioperative Mortalität.

FFCD 9102 (3)

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus

CALGB 9781 (6)

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer

Quellen

1.) Cooper JS, Guo MD, Herskovic A et al.:
Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective trial (RTOG 85-01). Radiation Therapy Oncology Group.
JAMA 281(1999):1623-7

2.) Minsky B, Neuberg D, Kelsen DP et al.:
Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus.
IJROBP 43(1999):517-23.

3.) Bedenne L, et al.:
Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.
JCO 25(2007):1160-8.

4.) Cunningham D, et al.:
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
NEJM 355(2006):11-20.

5.) Burmeister BH, et al.:
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.
Lancet Oncol 6(2005):659-68.

6.) Tepper J, et al.:
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
JCO 26(2008):1086-92

7.) Lee JL, et al.:
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma.
Ann Oncol 15(2004):947-54

8.) Ychou M, et al.:
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
JCO 29(2011):1715-21

9.) Stahl M, et al.:
Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.
JCO 27(2009):851-6.

10.) Minsky BD, et al.:
INT 0123 (Radiation Therapy Oncology Group 94–05) Phase III trial of combined-modality therapy for esophageal cancer: high-dose vs. standard-dose radiation therapy.
J Clin Oncol 20(2002):1167–1174

11.) Yang H, Liu H, Chen Y, et al.:
AME Thoracic Surgery Collaborative Group. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
J Clin Oncol 2018
doi:10.1200/JCO.2018 [Epub ahead of print]

12.) Hulshof M, et al.:
Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study).
J Clin Oncol 2021;39:2816-2824

Impressum                         Zuletzt geändert am 05.04.2015 6:41